Mammary Cell News Volume 5.15 | Apr 18 2013

LABORATORY RESEARCH

Diamond-Lipid Hybrids Enhance Chemotherapeutic Tolerance and Mediate Tumor Regression
Self-assembled nanodiamond-lipid hybrid particles (NDLPs) harness the potent interaction between the nanodiamond (ND)-surface and small molecules, while providing a mechanism for cell-targeted imaging and therapy of triple negative breast cancers. Epidermal growth factor receptor-targeted NDLPs are highly biocompatible particles that provide cell-specific imaging, promote tumor retention of ND-complexes, prevent epirubicin toxicities and mediate regression of triple negative breast cancers. [Adv Mater]
Abstract | Press Release

Investigation of SSEA-4 Binding Protein in Breast Cancer Cells
Researchers report the identification of an SSEA-4-binding protein in a breast cancer cell line, MCF-7. By using affinity capture and glycan microarray techniques, the intracellular FK-506 binding protein 4 (FKBP4) was identified to bind directly to SSEA-4. The biological significance of SSEA-4/FKBP4 interaction was investigated. [J Am Chem Soc] Abstract

Rac-Specific Guanine Nucleotide Exchange Factor DOCK1 Is a Critical Regulator of HER2-Mediated Breast Cancer Metastasis
Researchers aimed to identify Rac activators that could promote metastasis downstream of human epithelial growth factor receptor 2 (HER2). They investigated if Dedicator of Cytokinesis 1 (DOCK1), based on its evolutionarily conserved role in receptor tyrosine kinases-mediated Rac activation and cell invasion, could be a regulator of metastasis. They report that high expression of DOCK1 in HER2⁺ and basal breast cancer subtypes inversely correlates with human patients’ survival. [Proc Natl Acad Sci USA]
Abstract | Press Release

p130Cas Alters the Differentiation Potential of Mammary Luminal Progenitors by Deregulating C-Kit Activity
Investigators described that the adaptor protein p130Cas is a crucial regulator of mouse mammary epithelial cell differentiation. [Stem Cells] Abstract

Treatment of Triple-Negative Breast Cancer Using Anti-EGFR Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor
Scientists used epidermal growth factor receptor (EGFR) as a target for radioimmunotherapy and hypothesized that EGFR-directed radioimmunotherapy can deliver a continuous lethal radiation dose to residual tumors that are radiosensitized by poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors and chemotherapy. [J Nucl Med] Abstract | Press Release

Oncostatin-M Promotes Phenotypic Changes Associated with Mesenchymal and Stem Cell-Like Differentiation in Breast Cancer
Stimuli that induce epithelial-to-mesenchymal transition (EMT) and cancer stem cell-like features (‘stemness’) are poorly defined. Researchers aimed to determine whether oncostatin-M is a cell-extrinsic driver of EMT and/or stemness. [Oncogene] Abstract

CLINICAL RESEARCH

Short-Term Outcomes of Screening Mammography Using Computer-Aided Detection: A Population-Based Study of Medicare Enrollees
Researchers aimed to determine associations between computer-aided detection use during screening mammography and the incidence of ductal carcinoma in situ and invasive breast cancer, invasive cancer stage, and diagnostic testing. [Ann Intern Med] Abstract | Press Release

Cullin1 Is a Novel Marker of Poor Prognosis and a Potential Therapeutic Target in Human Breast Cancer
To investigate the role of Cullin1 (Cul1) in the development of breast cancer, researchers examined the expression of Cul1 in breast cancer tissues and analyzed the correlation between Cul1 expression and clinicopathologic variables and patients survival. [Ann Oncol] Abstract

Lymphatic and Angiogenic Candidate Genes Predict the Development of Secondary Lymphedema following Breast Cancer Surgery
The authors evaluated differences in phenotypic and genotypic characteristics in women who did and did not develop lymphedema following breast cancer treatment. [PLoS One] Full Article | Press Release

Functional and Structural Analysis of C-Terminal BRCA1 Missense Variants
Researchers aimed to functionally assess a set of 7 missense variants of uncertain significance (Q1409L, S1473P, E1586G, R1589H, Y1703S, W1718L and G1770V) located in the C-terminal region of BRCA1 by combining in silico prediction tools and structural analysis with a transcription activation assay. Structural analysis of the three variants located in the BRCT domains (Y1703S, W1718L and G1770V) reveals significant alterations of BRCT structure. Results suggest that variants Y1703S, W1718L and G1770V can be classified as likely pathogenic BRCA1 mutations. [PLoS One] Full Article | Press Release

Active Immunotherapy in HER2 Overexpressing Breast Cancer: Current Status and Future Perspectives
Researchers provide a focus on the following active vaccinal approaches under clinical investigation against HER2-overexpressing breast cancer: (i) peptide and protein based; (ii) DNA based; (iii) whole tumor cell based; (iv) dendritic cell based. Moreover, they discuss future challenges in the field, trying to define the best setting for the development of this innovative strategy, considering both immunological and clinical aspects of HER2 targeting. [Ann Oncol] Full Article

Intrathecal Administration of Trastuzumab for the Treatment of Meningeal Carcinomatosis in HER2-Positive Metastatic Breast Cancer: A Systematic Review and Pooled Analysis
This is the first systematic review/pooled analysis to synthesize all available data evaluating the efficacy and safety of intrathecal administration of trastuzumab for the treatment of leptomeningeal carcinomatosis in HER2-positive breast cancer patients. [Breast Cancer Res Treat] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Atossa Genetics to Provide ForeCYTE Breast Health Test to Two Leading Breast Centers in Texas
Atossa Genetics, Inc., The Breast Health Company™, will soon begin providing its patented ForeCYTE Breast Health Test for early detection of precursors to breast cancer at two breast centers in Texas: Aurora Breast Center in San Antonio and The Breast Center at Wellness Lubbock in Lubbock. [Marketwire, Incorporated] Press Release

Duke Oncologist Named as One of TIME’s 100 Most Influential People
Dr. Kimberly Blackwell, a clinical oncologist at the Duke Cancer Institute and one of the country’s leading breast cancer researchers, is included in this year’s roster of TIME magazine’s 100 most influential people. [Duke University] Press Release | Related Video

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Postdoctoral Position – Establishing the Role of Key Recurring Genetic Mutations in Endocrine Resistant Breast Cancer (AstraZeneca)

Postdoctoral Position – Breast Cancer Research (Albert Einstein College Medicine)

Postdoctoral Position – Hypoxia Signaling, Prolyl Hydroxylases and Cancer (UNC-Chapel Hill)

Postdoctoral Position – Breast Cancer (UT Southwestern Medical Center at Dallas)

Product Director – Breast Marketing (Genomic Health)

Postdoctoral Position – Cancer Biology (Louisiana State University Health Science Center)

Postdoctoral Researcher – Cancer Genomics and Computational Biology/Bioinformatics (University of British Columbia/Provincial Health Services Authority)

Postdoctoral Position – Breast Cancer Signaling (Weizmann Institute of Science)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.